I believe Regeneron included SAEs as endpoint in t
Post# of 145414
![](/assets/46931549/no_avatar_available_thumb.jpg)
Cytodyn will meets its endpoints, just slower for analysis than a/c dead/alive.
I didn’t follow manufacturing update as closely, I believe production this year decreased as manufacturing capacity given to approved drugs.
Presumably capacity will ramp quickly with EUA/approval and government assistance.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)